ClinicalTrials.gg
RecruitingNCT07422610Updated Sep 18, 2026

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

A Phase 1 interventional study of pelabresib in Advanced Malignancies and Hepatic Impairment, sponsored by Novartis Pharmaceuticals. Recruiting at 10 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lymphoma, Follicular by Novartis — 4 open to participants now, 5 under way, 2 of them phase 3. Lymphoma, Follicular · Novartis.

Planned enrollment
18th of 22
24 · median 60
Started
2026
the only one that year
Phase 1
7 of 24
1 open now
Registered
24th of 24
by date

Among the 24 studies in Lymphoma, Follicular by Novartis, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 1, and was the 24th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

4 of the 24 studies in Lymphoma, Follicular by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lymphoma, Follicular by Novartis, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.

Read the detailed description

This study consists of 2 main parts: Part 1 will assess the PK characteristics of pelabresib in participants with hepatic impairment versus normal hepatic function, and during Part 2, extended treatment with pelabresib may be offered in case of clinical benefit, as assessed by the investigator.

A participant is considered to have started the study and entered the screening period upon signing the informed consent form (ICF). Enrollment occurs when participant receive their first dose of study treatment via the IRT system. A participant is considered to have completed the study if they have completed all phases of the study including the end of treatment (EOT) and 30-day safety follow-up visits. Participants with hematological malignancies will be followed up every 3 months beyond EOT.

Part 1: Impact of hepatic impairment on pelabresib PK

In Part 1, the PK characteristics of pelabresib will be investigated in participants with advanced malignancies comprising 2 different study groups according to their hepatic function:

  • Group 1 includes participants with normal hepatic function
  • Group 2 includes participants with moderate or severe HI

Following completion of Part 1, participants can directly proceed to Part 2

Part 2: Continued treatment After completing Part 1, in case of clinical benefit, participants can continue with pelabresib treatment in Part 2 until the end of study (EOS) is reached, until the participant meets discontinuation criteria, or until they receive pelabresib treatment via alternative means of access, whichever occurs first. Clinical benefit is determined by the investigator.

End of treatment visit An EOT visit is required for all participants within 7 days of the last dose of pelabresib treatment (or within 7 days of the decision to discontinue treatment, if the decision was made > 7 days after the last dose).

30-day safety follow-up All participants will be followed up for AEs and serious AEs (SAEs) for 30 days (±3 days) following the last dose of pelabresib. If the participant starts another anticancer treatment or switches to pelabresib treatment via an alternative source (e.g., in an extension study or commercially available pelabresib), the safety follow-up will end at the time of the first administration of the respective treatment.

Leukemic transformation follow-up for participants with hematological malignancies After the EOT visit and the 30-Day safety follow-up visit, participants with hematological malignancies will be followed up every 3 months for leukemic transformation until the overall end of the study, confirmation of AML, withdrawal of consent, loss to follow-up, or death, whichever occurs first.

03

Conditions studied

  • Advanced Malignancies and Hepatic Impairment

Keywords

  • Hepatic impairment (HI)
  • Moderate or severe hepatic impairment
  • Advanced malignancies
  • Pharmacokinetics (PK)
  • Bromodomain and extraterminal (BET)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Is at least 18 and not older than 75 years of age at the time of signing the .
  • Group 1 only: There is a matching participant in Group 2 and an enrollment slot is available for the Group 1 participant.
  • Has a confirmed documented diagnosis of an advanced for which no standard and/or curative treatment options are available.
  • Has the following acceptable laboratory assessments prior to the first dose of study treatment:

    1. count ≥ 150 × 109 /L in the absence of thrombopoietic factors or transfusions within 2 weeks of the screening assessment
    2. (ANC) ≥ 1 × 109 /L in the absence of granulocyte growth factors
    3. Adequate renal function ( of ≥30 mL/min, calculated using Cockcroft-Gault formula)
    4. Peripheral blood blast count \< 5%. Assessment of blasts in bone marrow is not mandatory at screening, however, blasts must be \<5% if the assessment is performed.
  • Has a ≥3 months.
  • Has fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy .
  • Hepatic function:

    1. Is in Group 1 and is classified as having normal hepatic function based on NCI-ODWG criteria (i.e., total ≤ (ULN) and (AST) ≤ ULN); or
    2. Is in Group 2 and has stable moderate or severe HI as defined by NCI ODWG criteria:

      • moderate HI: total bilirubin >1.5 × to 3 × ULN, and any AST value
      • severe HI: total bilirubin > 3 × ULN, and any AST value

Key Exclusion Criteria:

  • Has a history of to the study treatment or its or to drugs of similar chemical class.
  • Has any other medical condition which, in the investigator's opinion, makes the participant unsuitable for the study.
  • Is a female participant who is pregnant (confirmed by a pregnancy test at screening) or is breastfeeding.
  • Is a woman of (WOCBP) who does not agree to follow the guidance during the treatment period and for at least 184 days after the last dose of study treatment, and who does not agree to refrain from donating eggs during this period.
  • Has esophageal variceal bleeding within the past 2 months prior to the first dose of pelabresib.
  • Has an active infection.
  • Has impaired cardiac function or clinically significant cardiac diseases
  • Has a GI tumor, impaired GI function, GI disease, or significant resection of stomach or other portion of the GI tract that could alter the absorption of pelabresib, including any unresolved nausea, vomiting, or diarrhea.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group 1 (normal hepatic function)

    Part 1: Participants receive pelabresib 125 mg orally (PO) once daily (QD) for 14 days, followed by a 7-day break (1 cycle = 21 days). If clinical benefit is observed, treatment continues in Part 2 until end of study (EOS), discontinuation criteria, or alternative access.

    Drug: pelabresib

  • Experimental
    Group 2 (moderate or severe HI)

    Part 1: Participants receive pelabresib 125 mg orally (PO) once daily (QD) for 14 days, followed by a 7-day break (1 cycle = 21 days). If clinical benefit is observed, treatment continues in Part 2 until end of study (EOS), discontinuation criteria, or alternative access.

    Drug: pelabresib

Interventions

  • pelabresib 125 mg orally (PO) once daily (QD) for 14 days, followed by a 7-day break

    Also known as: DAK539 (formerly CPI-0610)

06

What researchers measure

Primary outcomes

  1. Area Under the Curve from 0 to 24 hours on Day 14 (AUC₀-24h,D14) of pelabresib at steady state per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. AUC₀-24h,D14 of pelabresib at steady state per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14: 0, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose (1 cycle = 21 days)

  2. Maximum Plasma Concentration on Day 14 (Cmax,D14) of pelabresib at steady state per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. Cmax,D14 of pelabresib at steady state per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14 (1 cycle = 21 days)

  3. Apparent Clearance (CL/F) of pelabresib at steady state per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. CL/F of pelabresib at steady state per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14 (1 cycle = 21 days)

  4. Apparent Volume of Distribution (V/F) of pelabresib at steady state per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. V/F of pelabresib at steady state per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14 (1 cycle = 21 days)

  5. Terminal Half-Life (T½) of pelabresib at steady state per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. T½ of pelabresib at steady state per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14 (1 cycle = 21 days)

Secondary outcomes

  1. Maximum Plasma Concentration on Day 1 (Cmax,D1) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. Cmax,D1 of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (1 cycle = 21 days)

  2. Area Under the Curve from 0 to 24 hours on Day 1 (AUC₀-24h,D1) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. AUC₀-24h,D1 of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1: 0, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose (1 cycle = 21 days)

  3. Trough Concentration on Day 14 (Ctrough,D14) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. Ctrough,D14 of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14: predose (1 cycle = 21 days)

  4. Accumulation Ratio (Rac) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. Rac of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1: Day 14 compared to Day 1 (1 cycle = 21 days)

  5. Time to Maximum Concentration (Tmax) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. Tmax of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1: Day 1 and Day 14 (1 cycle = 21 days)

  6. Terminal Half-Life (T½) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. T½ of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (1 cycle = 21 days)

  7. Fraction Unbound (fu) of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. fu of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 14: 0, 2, and 8 hours postdose (1 cycle = 21 days)

  8. fu-adjusted AUC of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. fu-adjusted AUC of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1: Day 1 and Day 14 (1 cycle = 21 days)

  9. fu-adjusted Cmax of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. fu-adjusted Cmax of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1: Day 1 and Day 14 (1 cycle = 21 days)

  10. fu-adjusted Ctrough of pelabresib per study group

    Venous whole blood samples will be collected for pharmacokinetics characterization. fu-adjusted Ctrough of pelabresib per study group will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 and Day 14: predose (1 cycle = 21 days)

  11. Number of Participants with adverse events (AEs), serious AEs (SAEs)

    Incidence of adverse events by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.

    Time frame: Through study completion, an average of 28 months

07

Study locations

10 of 10 sites recruiting
  • Novartis Investigative Site
    Bordeaux, 33075, France
    Recruiting
  • Novartis Investigative Site
    Saint-Herblain, 44805, France
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20132, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20141, Italy
    Recruiting
  • Novartis Investigative Site
    Candiolo, TO 10060, Italy
    Recruiting
  • Novartis Investigative Site
    Pozuelo de Alarcón, Madrid 28223, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08023, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28040, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28050, Spain
    Recruiting
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's planned 25 months is below that.

Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Feb 20, 2026
StartActual
May 19, 2026
Primary completionEst.
Jun 28, 2028
CompletionEst.
Aug 2, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422610
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
May 19, 2026
Primary completion
Jun 28, 2028 (estimated)
Completion
Aug 2, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPI-0610

Start the discussion